KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.85

Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial.

Carole Mercier, Charlotte Billiet, Piet Ost, Katrien Vandecasteele, Geert De Kerf, Michaël Claessens, Steven Van Laere, Peter Vermeulen, Luc Dirix, Yolande Lievens, Dirk Verellen, Piet Dirix

J Clin Oncol 43(19) 2164-2172

PMID40340551
PMCID-
DOI10.1200/JCO-24-01447
发表日期2025-05-09
入排依据:Phase III randomized trial of a non-drug intervention (radiotherapy) for painful bone metastases. Primary endpoint is complete pain response, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

PURPOSE: To test whether dose-escalated single fraction (SF) stereotactic body radiotherapy (SBRT) of 20 Gy to painful bone metastases is superior to conventional SF three-dimensional (3D) conformal radiotherapy (RT) to a standard dose of 8 Gy in achieving complete pain response (CR). METHODS: A single-blind, randomized, controlled, phase III trial (ROBOMET) included 126 patients with up to three painful bone metastases, randomly assigned between April 2019 and October 2022 at multiple centers in Belgium. Inclusion criteria were uncomplicated painful bone metastases (worst pain score ≥2 on a 0-10 pain scale) arising from a solid tumor. Treatment consisted of either a single SBRT fraction of 20 Gy or a single conventional RT fraction of 8 Gy. The primary end point was the proportion of patients with a CR 1 month after RT scored according to the International Consensus on Palliative Radiotherapy Endpoints analyzed as per an intention-to-treat principle. RESULTS: After 1 month, 16 of 63 (25% [95% CI, 15 to 38]) patients treated with conventional RT achieved CR versus 23 of 63 (37% [95% CI, 25 to 50]) treated with SBRT (P = .25). After 3 months, 15 of 63 (24% [95% CI, 14 to 36]) patients achieved CR after conventional RT versus 21 of 63 (33% [95% CI, 22 to 46]) after SBRT (P = .32). Among patients evaluable after 3 months and treated per protocol, the SBRT group had more complete responders (21/39, 54% [95% CI, 37 to 70]) than the conventional RT group (15/48, 31% [95% CI, 19 to 46]; P = .048). CONCLUSION: SBRT failed to demonstrate improved CR rates after 1 month.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。